Investors
Investor Portal
The Investor Portal allows you to view your personal share information, register to receive Novo Nordisk Annual Report and Annual General Meeting notification, and change your contact information.
Both a Danish and an English version of the Investor Portal is available. To log-on to the Investor Portal use your VP-reference or NEM-ID:
Access Novo Nordisk Investor Portal (UK)
Log på Novo Nordisk Investor Portal (DK)
The Investor Portal is administered by VP Securities A/S. VP Securities A/S is a Central Securities Depository (CSD) in Denmark authorised by the Danish Financial Supervisory Authority (Finanstilsynet) according to the Danish Securities Trading Act. Learn how VP Securities A/S process personal data.
For further information, please refer to our Notice of Personal Data
Processing.
Holders of physical share certificates and interim certificates in former Nordisk Gentofte A/S and Novo Industri A/S are entitled to convert these into registered shares in Novo Nordisk A/S and in Novozymes A/S.
Holders of such certificates are thus encouraged to contact Danske
Bank, Corporate Actions, via contact details below no
later than November 4, 2018 in order to have their shareholdings
registered and the physical certificates converted into registered
shares in Novo Nordisk A/S and Novozymes A/S.
If the conversion is not completed on November 4, 2018, the corresponding shares will be sold pursuant to the Danish Companies Act. Holders of physical share certificates and interim certificates will be entitled to collect the net proceeds of the share sale within a period of 3 years following the sale.
Click here to see the embedded announcement as published on Virk.dk for further information (in Danish).
The above applies to holders of physical share certificates and interim certificates in former Nordisk Gentofte A/S and Novo Industri A/S only and does not affect shareholders of registered shares in Novo Nordisk A/S.
Danske Bank, 3886 Corporate Actions,
Holmens Kanal 2-12,
1092 København K,
Telephone: (+45) 45 14 36 94
E-mail: corporate.actions@danskebank.dk
FAQ about Investor Portal
The total dividend for 2019 was DKK 8.35 for each A and B share, consisting of an interim dividend of DKK 3.00 (paid in August 2019) and a final dividend of DKK 5.35 (paid in March 2020) for each A and B share.
The interim dividend for 2020 of DKK 3.25 for each A and B share of DKK 0.20 was paid in August 2020.
The share buyback programme is a way for Novo Nordisk to return excess capital to the investors. By buying back shares and reducing the share capital, the value of the remaining outstanding shares increases.
You can look up and download historical share prices in the Shareholder tools section. You can also calculate the return on the investment you have made in Novo Nordisk shares
No – we will automatically get your new address.
Yes - you will have to log on to Investor Portal and change the email address:
Access Novo Nordisk Investor Portal (UK)
Log på Novo Nordisk Investor Portal (DK)
ADR is an abbreviation for an American Depository Receipt. An ADR is a receipt for the shares of a foreign-based corporation held in the vault of a U.S. bank, entitling the shareholder to all dividends and capital gains.
The depository bank responsible for Novo Nordisk’s ADR is JP Morgan and the contact information is:
J.P. Morgan
1 Chase Manhattan Plaza, Floor 58
New York,
NY 10005
(866) JPM-ADRS (866 576-2377)
adr@jpmorgan.com
SHARE magazine
Q2 2020
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Clinical results support Strategic Aspiration for obesity treatment
- Novo Nordisk acquires Corvidia Therapeutics and expands presence in cardiovascular disease
- Lose or reuse? How we are repurposing our insulin pens
- A deep dive into NASH and Novo Nordisk’s activities in tackling this disease
- Highlights from the first six months of 2020
Q1 2020
SHARE Magazine
UK | SHARE Magazine DK
Index
- Message from the CEO
- An unprecedented challenge: our response to COVID-19
- Rybelsus® approved in the EU
- Obesity through the lens: the truth from within
- Prevention or cure? When it comes to type 1 diabetes, we are working on both
- Highlights from the first three months of 2020
Q3 2019
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- A new era in diabetes care: Rybelsus® approved in the USA
- New affordability initiatives to be launched in the USA
- People and purpose: Monique Carter on driving culture change at Novo Nordisk
- Intensifying China’s fight against diabetes
- Highlights from the first six months of 2019
Q2 2019
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- A new mindset for environmental responsibility
- Obesity: The brain is the battleground
- Outcomes trials: Can semaglutide go even further in addressing patient needs?
- Maximising the growth potential
- Listen and lead: Ludovic Helfgott on returning biopharm to growth
- Highlights from the first six months of 2019
Q1 2019
SHARE Magazine UK | SHARE Magazine DK
Index
- Message from the CEO
- Oral semaglutide filed in the US and EU
- The day I fired my doctor
- Safely in the Rainbow
- Shaped tablet key to oral delivery of insulin
- Novo Nordisk addresses affordable insulin
- Accelerating growth in Latin America
- Highlights from the first three months of 2019
Q3 2018
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first nine months of 2018
- Tresiba® revitalised with new ‘Hypos matter’
- Novo Nordisk research centre opens in oxford
- Connected insulin pens poised for launch
Q2 2018
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first six months of 2018
- Oral semaglutide shows promising results
- Ozempic® heading for the European market
- Novo Nordisk focuses on treating obesity
- Red Cross and Novo Nordisk enters partnership
Q1 2018
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first three months of 2018
- Oral semaglutide shows promising results
- Ozempic® approved in the EU and Japan
- First phase 3a trial with oral semaglutide completed
- Updated Tresiba® label approved in the USA
- How Novo Nordisk’s products in Cuba
Q3 2017
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first nine months of 2017
- Camilla Sylvest joins executive management
- SUSTAIN 7: Semaglutide compared to dulaglutide
- Victoza® CV label approved in the US and the EU
- Fiasp® a fast-acting insulin approved in the US
- Ambitious global goal: To prevent 100 million new cases of diabetes by 2045
Q2 2017
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first six months of 2017
- Label update for Tresiba® submitted in the US
- A step closer towards a CV indication for Victoza®
- Phase 2 obesity data for semaglutide
- New data on Xultophy®
- Why Novo Nordisk is helping refugees
Q1 2017
SHARE Magazine UK | SHARE Magazine DK
Index
- Letter from the CEO, Lars Fruergaard Jørgensen
- Highlights from the first three months of 2017
- Doug Langa new head of North America Operations
- Fiasp® launched in Canada and EU markets
- New research centre in Oxford
- CHMP endorses Refixia®
- World Diabetes Foundation 15 th anniversary
SHARE INFORMATION
Share monitor
Investors
Share price
{{priceData.date}} {{priceData.time}}
